ArticleWorld journal of urology2025
Robotic versus open radical cystectomy: factors influencing approach Selection, predictors of surgical Conversion and their implications for patient outcomes.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- White paper: robotic cholecystectomy-new technology but safe principles still apply.Surgical endoscopy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRobot-assisted radical cystectomy (RARC) use for bladder cancer (BC) treatment is increasing, offering similar oncologic outcomes to open radical cystectomy (ORC) with better perioperative results. We assessed factors driving RARC selection, predictors of conversion to open surgery, and impacts on mortality and morbidity.
methodsWe retrospectively analyzed the National Cancer Database (NCDB) (2010–2021) for patients with localized BC undergoing RARC versus ORC. Proportions in approach use were assessed, and multivariable logistic regression identified predictors of approach selection. RARC conversion rates and conversion predictors were analyzed. 30-/90-day mortality and 30-day readmission were compared between converted and non-converted cases using adjusted odds ratios (aOR) and 95% confidence intervals (CI).
resultsAmong 29,215 patients with localized BC, 9,954 (34.1%) underwent RARC. Usage rose from 18.1% in 2010 to 48.7% in 2021 (p < 0.001), highest in non-muscle invasive BC (NMIBC) (36.0%; p < 0.001). Predictors of RARC adoption over ORC included NMIBC diagnosis (aOR 1.22, 95% CI 1.10–1.35), neoadjuvant chemotherapy (1.49, 1.34–1.66), and private insurance (1.68, 1.32–2.16). RARC usage was less likely for cN2-3 (0.73, 0.61–0.86) and prior radiation (0.60, 0.43–0.85). Among RARC cases, 288 (2.9%) required intraoperative conversion to open surgery. Low-volume centers (< 10 cases: 2.33, 1.66–3.28; 10–19 cases: 1.89, 1.26–2.83) had higher conversion risk. Converted cases had significantly higher 90-day (11.9% vs. 5.1%; 2.53, 1.72–3.72) mortality and 30-day readmission (14.3% vs. 8.5%; 1.79, 1.28–2.51).
conclusionsRARC use increased, especially in NMIBC cases. Its adoption was driven by NMIBC diagnosis, neoadjuvant chemotherapy, and insurance; low caseload predicted conversion to open surgery and worse outcomes, informing patient selection.
Indexed as
Identifiers
41165824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.